Quantcast
Home > Quotes > TXMD
x

TherapeuticsMD, Inc. Common Stock (TXMD) Quote & Summary Data

TXMD 
$5.53
*  
0.11
2.03%
Get TXMD Alerts
*Delayed - data as of Oct. 15, 2018 15:20 ET  -  Find a broker to begin trading TXMD now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    TXMD Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 5.53 / $ 5.54
1 Year Target
15.5
Today's High / Low
$ 5.615 / $ 5.415
Share Volume
1,761,444
50 Day Avg. Daily Volume
2,519,532
Previous Close
$ 5.42
52 Week High / Low
$ 7.66 / $ 4.34
Market Cap
1,301,831,064
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -0.43
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.9

Intraday Chart

Shares Traded

Share Volume:
1,761,444
50 Day Avg. Daily Volume:
2,519,532

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.43

Trading Range

The current last sale of $5.53 is 27.42% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 5.615 $ 7.66
 Low: $ 5.415 $ 4.34

ETFs with TXMD as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
1.35% SPDR S&P Pharmaceuticals ETF (XPH) +2.55 (6.10%)
1.05% iShares U.S. Pharmaceutical ETF (IHE) +10.26 (6.94%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a women's health care company focused on creating and commercializing products targeted exclusively for women. Currently, we are focused on pursuing the regulatory approvals and pre-commercialization activities necessary for commercialization of our advanced hormone therapy pharmaceutical products. Our drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes and vaginal discomfort. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or in combination, with the aim of demonstrating clinical efficacy at lower doses, thereby enabling an enhanced side-effect profile compared with competing products.  ... More ...  


Risk Grade

Where does TXMD fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 5.46
Open Date:
Oct. 15, 2018
Close Price:
$ 5.42
Close Date:
Oct. 12, 2018

Consensus Recommendation

Analyst Info